Ultragenyx Settles DOJOLVI Patent Litigation with Esjay Pharma

Ultragenyx Pharmaceutical Inc. and Baylor Research Institute have reached a settlement agreement with Esjay Pharma Private Limited and Esjay Pharma LLC, resolving patent litigation related to the Company's DOJOLVI® (triheptanoin) oral liquid. The litigation stemmed from Esjay's submission of an Abbreviated New Drug Application seeking approval for a generic version of DOJOLVI. Under the terms, Ultragenyx will grant Esjay a non-exclusive, royalty-free license to market its generic DOJOLVI starting January 1, 2033, with a potential extension to July 1, 2033, if pediatric exclusivity is granted. Other similar patent litigations concerning DOJOLVI remain ongoing.